MiNK Therapeutics (NASDAQ:INKT – Get Free Report) is anticipated to release its earnings data before the market opens on Tuesday, March 18th. Analysts expect MiNK Therapeutics to post earnings of ($0.50) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.
MiNK Therapeutics Stock Performance
MiNK Therapeutics stock opened at $8.49 on Friday. The stock’s 50 day moving average price is $8.94 and its 200 day moving average price is $7.74. The firm has a market capitalization of $33.65 million, a PE ratio of -2.18 and a beta of 0.16. MiNK Therapeutics has a one year low of $4.56 and a one year high of $19.00.
Analyst Ratings Changes
Separately, HC Wainwright boosted their price target on MiNK Therapeutics from $9.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, February 25th.
MiNK Therapeutics Company Profile
MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.
See Also
- Five stocks we like better than MiNK Therapeutics
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- What is the Euro STOXX 50 Index?
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
